Fig. 5

Serum from a patient with Vaccine-induced myocarditis provokes hypertrophy, increasing BNP expression. (A) Hypertrophy assay, representative confocal images of treatments are shown (Green calcein-stained cytoplasm and Blue Draq5 stained nuclei) Hypertrophy assay, representative confocal images of treatments are shown (Green calcein-stained cytoplasm and Blue Draq5 stained nuclei). (B) Cell-surface quantification in treated groups, CTRL, (Gray bars), Acute recovery (Red bars), recovery (Pink bars). C and D. mRNA expression of stress and hypertrophic markers BNP and TnC, respectively. RNA was purified by the Trizol method and converted to cDNA to perform a qPCR. HPRT was used as a control gene. For statistical analysis, an ANOVA was calculated considering mRNA expression of stress and hypertrophic markers BNP and TnC, respectively. RNA was purified by the Trizol method and converted to cDNA to perform a qPCR. HPRT was used as a control gene. For statistical analysis, an ANOVA was calculated considering p < 0.05 * and p < 0.01 **. We also determined cardiac stress and injury markers after cells’ treatment with control serum, acute-phase serum, and recoveryphase serum. Only the serum in the acute phase increased BNP, a cardiac marker of hemodynamic stress and ventricular dysfunction (Fig. 5-C). We did not observe the effects of sera treatments on the hs-cTnI expression (Fig. 5-D)